Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2017 | Research

Vitamin D receptor, Retinoid X receptor and peroxisome proliferator-activated receptor γ are overexpressed in BRCA1 mutated breast cancer and predict prognosis

Authors: Sabine Heublein, Doris Mayr, Alfons Meindl, Alexandra Kircher, Udo Jeschke, Nina Ditsch

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2017

Abstract

Background

BRCA1 mutated breast cancers are commonly diagnosed as negative for classical hormone receptors i.e. estrogen receptor, progesterone receptor and/or Her2. Due to these common targets being absent the application of anti-endocrine therapies is rather limited and a certain focus has been set on discovering alternative target molecules. We recently highlighted thyroid hormone receptors (TRs) to predict prognosis in breast cancer patients that had been diagnosed a BRCA1 germline mutation. Vitamin D Receptor (VDR), Retinoid X Receptor (RXR) and Peroxisome Proliferator-activated Receptor γ (PPARγ) are known to interact with TRs by forming functional heterodimers. Whether VDR, RXR or PPARγ are expressed in BRCA1 mutated breast cancer or may even be present in case of triple negativity is not known. Hence the current study aimed to investigate VDR, RXR and PPARγ in BRCA1 ^mut breast cancer and to test whether any of the three may be associated with clinico-pathological criteria including overall survival.

Methods

This study analyzed VDR, RXR and PPARγ by immunohistochemistry in BRCA1 associated (n = 38) and sporadic breast cancer (n = 79). Receptors were quantified by applying an established scoring system (IR-score) and were tested for association with clinico-pathological variables.

Results

VDR, RXR and PPARγ were detected in over 90% of triple negative BRCA1 ^mut breast cancer and were significantly (VDR: p < 0.001, RXR: p = 0.010, PPARγ: p < 0.001) overexpressed in BRCA1 mutated as compared to sporadic cancer cases. VDR and RXR positivity predicted prolonged overall survival only in BRCA1 mutated cases while such association was not observed in sporadic breast cancer.

Conclusions

In conclusion, this is the first study to describe VDR, RXR and PPARγ in BRCA1 mutated breast cancer. Based on the data presented here these receptors may be hypothesized to potentially evolve as interesting markers or even targets in hereditary breast cancer. However, independent studies are indispensable thus to confirm this hypothesis.

Available only for authorised users

Nadji M, Gomez-Fernandez C, Ganjei-Azar P, Morales AR. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol. 2005;123(1):21–7.CrossRefPubMed

Allred DC. Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer. Mod Pathol. 2010;23 Suppl 2:S52–59.CrossRefPubMed

Tomao F, Papa A, Zaccarelli E, Rossi L, Caruso D, Minozzi M, Vici P, Frati L, Tomao S. Triple-negative breast cancer: new perspectives for targeted therapies. OncoTargets Ther. 2015;8:177–93.CrossRef

Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer Jr CE, Martino S, Rastogi P, Gralow J, Swain SM, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014;32(33):3744–52.CrossRefPubMedPubMedCentral

Yadav BS, Sharma SC, Chanana P, Jhamb S. Systemic treatment strategies for triple-negative breast cancer. World J Clin Oncol. 2014;5(2):125–33.CrossRefPubMedPubMedCentral

Peshkin BN, Alabek ML, Isaacs C. BRCA1/2 mutations and triple negative breast cancers. Breast Dis. 2010;32(1–2):25–33.PubMed

Stevens KN, Vachon CM, Couch FJ. Genetic susceptibility to triple-negative breast cancer. Cancer Res. 2013;73(7):2025–30.CrossRefPubMedPubMedCentral

Heublein S, Mayr D, Meindl A, Angele M, Gallwas J, Jeschke U, Ditsch N. Thyroid hormone receptors predict prognosis in BRCA1 associated breast cancer in opposing ways. PLoS One. 2015;10(6):e0127072.CrossRefPubMedPubMedCentral

Zhang K, Song L. Association between vitamin D receptor gene polymorphisms and breast cancer risk: a meta-analysis of 39 studies. PLoS One. 2014;9(4):e96125.CrossRefPubMedPubMedCentral

10.

Bonofiglio D, Cione E, Vizza D, Perri M, Pingitore A, Qi H, Catalano S, Rovito D, Genchi G, Ando S. Bid as a potential target of apoptotic effects exerted by low doses of PPARgamma and RXR ligands in breast cancer cells. Cell Cycle. 2011;10(14):2344–54.CrossRefPubMed

11.

Yasmin R, Kannan-Thulasiraman P, Kagechika H, Dawson MI, Noy N. Inhibition of mammary carcinoma cell growth by RXR is mediated by the receptor’s oligomeric switch. J Mol Biol. 2010;397(5):1121–31.CrossRefPubMedPubMedCentral

12.

Shankaranarayanan P, Rossin A, Khanwalkar H, Alvarez S, Alvarez R, Jacobson A, Nebbioso A, de Lera AR, Altucci L, Gronemeyer H. Growth factor-antagonized rexinoid apoptosis involves permissive PPARgamma/RXR heterodimers to activate the intrinsic death pathway by NO. Cancer Cell. 2009;16(3):220–31.CrossRefPubMed

13.

Fischer C, Kuchenbacker K, Engel C, Zachariae S, Rhiem K, Meindl A, Rahner N, Dikow N, Plendl H, Debatin I, et al. Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German hereditary breast and ovarian cancer consortium. J Med Genet. 2013;50(6):360–7.CrossRefPubMed

14.

Ditsch N, Toth B, Himsl I, Lenhard M, Ochsenkuhn R, Friese K, Mayr D, Jeschke U. Thyroid hormone receptor (TR)alpha and TRbeta expression in breast cancer. Histol Histopathol. 2013;28(2):227–37.PubMed

15.

Ditsch N, Mayr D, Lenhard M, Strauss C, Vodermaier A, Gallwas J, Stoeckl D, Graeser M, Weissenbacher T, Friese K, et al. Correlation of thyroid hormone, retinoid X, peroxisome proliferator-activated, vitamin D and oestrogen/progesterone receptors in breast carcinoma. Oncol Lett. 2012;4(4):665–71.PubMedPubMedCentral

16.

Ditsch N, Toth B, Mayr D, Lenhard M, Gallwas J, Weissenbacher T, Dannecker C, Friese K, Jeschke U. The association between vitamin D receptor expression and prolonged overall survival in breast cancer. J Histochem Cytochem. 2012;60(2):121–9.CrossRefPubMedPubMedCentral

17.

Ditsch N, Vrekoussis T, Lenhard M, Ruhl I, Gallwas J, Weissenbacher T, Friese K, Mayr D, Makrigiannakis A, Jeschke U. Retinoid X receptor alpha (RXRalpha) and peroxisome proliferator-activated receptor gamma (PPARgamma) expression in breast cancer: an immunohistochemical study. in vivo. 2012;26(1):87–92.PubMed

18.

Lenhard M, Lennerova T, Ditsch N, Kahlert S, Friese K, Mayr D, Jeschke U. Opposed roles of follicle-stimulating hormone and luteinizing hormone receptors in ovarian cancer survival. Histopathology. 2011;58(6):990–4.CrossRefPubMed

19.

Heublein S, Vrekoussis T, Mayr D, Friese K, Lenhard M, Jeschke U, Dian D. Her-2/neu expression is a negative prognosticator in ovarian cancer cases that do not express the follicle stimulating hormone receptor (FSHR). J Ovarian Res. 2013;6(1):6.CrossRefPubMedPubMedCentral

20.

McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol. 2005;23(36):9067–72.CrossRefPubMed

21.

Foulkes WD, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N, Trudel M, Akslen LA. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2003;95(19):1482–5.CrossRefPubMed

22.

Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Modern Pathol. 2006;19(2):264–71.CrossRef

23.

Won JR, Gao D, Chow C, Cheng J, Lau SY, Ellis MJ, Perou CM, Bernard PS, Nielsen TO. A survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standard. Modern Pathol. 2013;26(11):1438–50.CrossRef

24.

Satih S, Savinel H, Rabiau N, Fontana L, Bignon YJ, Bernard-Gallon DJ. Expression analyses of nuclear receptor genes in breast cancer cell lines exposed to soy phytoestrogens after BRCA2 knockdown by TaqMan Low-Density Array (TLDA). J Mol Signal. 2009;4:3.CrossRefPubMedPubMedCentral

25.

Singh KK, Shukla PC, Yanagawa B, Quan A, Lovren F, Pan Y, Wagg CS, Teoh H, Lopaschuk GD, Verma S. Regulating cardiac energy metabolism and bioenergetics by targeting the DNA damage repair protein BRCA1. J Thorac Cardiovasc Surg. 2013;146(3):702–9.CrossRefPubMed

26.

Pickholtz I, Saadyan S, Keshet GI, Wang VS, Cohen R, Bouwman P, Jonkers J, Byers SW, Papa MZ, Yarden RI. Cooperation between BRCA1 and vitamin D is critical for histone acetylation of the p21waf1 promoter and growth inhibition of breast cancer cells and cancer stem-like cells. Oncotarget. 2014;5(23):11827–46.CrossRefPubMedPubMedCentral

27.

Deng C, Ueda E, Chen KE, Bula C, Norman AW, Luben RA, Walker AM. Prolactin blocks nuclear translocation of VDR by regulating its interaction with BRCA1 in osteosarcoma cells. Mol Endocrinol. 2009;23(2):226–36.CrossRefPubMed

28.

Calvo V, Beato M. BRCA1 counteracts progesterone action by ubiquitination leading to progesterone receptor degradation and epigenetic silencing of target promoters. Cancer Res. 2011;71(9):3422–31.CrossRefPubMed

29.

Tsao WC, Wu HM, Chi KH, Chang YH, Lin WW. Proteasome inhibitors induce peroxisome proliferator-activated receptor transactivation through RXR accumulation and a protein kinase C-dependent pathway. Exp Cell Res. 2005;304(1):234–43.CrossRefPubMed

30.

Lattuada D, Vigano P, Mangioni S, Sassone J, Di Francesco S, Vignali M, Di Blasio AM. Accumulation of retinoid X receptor-alpha in uterine leiomyomas is associated with a delayed ligand-dependent proteasome-mediated degradation and an alteration of its transcriptional activity. Mol Endocrinol. 2007;21(3):602–12.CrossRefPubMed

31.

Lee WP, Jena S, Doherty D, Ventakesh J, Schimdt J, Furmick J, Widener T, Lemau J, Jurutka PW, Thompson PD. Sentrin/SUMO specific proteases as novel tissue-selective modulators of vitamin D receptor-mediated signaling. PLoS One. 2014;9(2):e89506.CrossRefPubMedPubMedCentral

32.

Al-Azhri J, Zhang Y, Bshara W, Zirpoli G, McCann SE, Khoury T, Morrison CD, Edge SB, Ambrosone CB, Yao S. Tumor Expression of Vitamin D Receptor and Breast Cancer Histopathological Characteristics and Prognosis. Clin Cancer Res. 2017;23:97-103.

33.

Berger U, McClelland RA, Wilson P, Greene GL, Haussler MR, Pike JW, Colston K, Easton D, Coombes RC. Immunocytochemical determination of estrogen receptor, progesterone receptor, and 1,25-dihydroxyvitamin D3 receptor in breast cancer and relationship to prognosis. Cancer Res. 1991;51(1):239–44.PubMed

34.

Thakkar A, Wang B, Picon-Ruiz M, Buchwald P, Ince TA. Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer. Breast Cancer Res Treat. 2016;157(1):77–90.CrossRefPubMedPubMedCentral

35.

Elstner E, Williamson EA, Zang C, Fritz J, Heber D, Fenner M, Possinger K, Koeffler HP. Novel therapeutic approach: ligands for PPARgamma and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cells. Breast Cancer Res Treat. 2002;74(2):155–65.CrossRefPubMed

36.

Wu K, Kim HT, Rodriquez JL, Hilsenbeck SG, Mohsin SK, Xu XC, Lamph WW, Kuhn JG, Green JE, Brown PH. Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epidemiol Biomarkers Prev. 2002;11(5):467–74.PubMed

Title: Vitamin D receptor, Retinoid X receptor and peroxisome proliferator-activated receptor γ are overexpressed in BRCA1 mutated breast cancer and predict prognosis
Authors: Sabine Heublein
Doris Mayr
Alfons Meindl
Alexandra Kircher
Udo Jeschke
Nina Ditsch
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2017
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/s13046-017-0517-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2017

Long non-coding RNA NKILA inhibits migration and invasion of non-small cell lung cancer via NF-κB/Snail pathway

Stathmin is overexpressed and regulated by mutant p53 in oral squamous cell carcinoma

Distinct activity of the bone-targeted gallium compound KP46 against osteosarcoma cells - synergism with autophagy inhibition

FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib

E2F8, a direct target of miR-144, promotes papillary thyroid cancer progression via regulating cell cycle

Dihydroartemisinin inhibits TCTP-dependent metastasis in gallbladder cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer